In February 2026, scientists achieved a breakthrough by turning methane into high-value medicines, including the hormone therapy drug dimestrol, using what type of catalyst?

In a significant scientific advancement reported in February 2026, researchers successfully transformed methane, the primary component of natural gas, into high-value medicines, including the hormone therapy drug dimestrol. This groundbreaking process relied on a specialized iron-based catalyst. Methane is notoriously difficult to convert into other useful compounds due to the stability of its carbon-hydrogen bonds, making this direct synthesis a long-sought-after goal in chemistry.

The ingenuity of this breakthrough lies in the design of an LED-driven photocatalyst that effectively activates methane molecules. This iron-based catalyst facilitates the conversion of methane into complex chemical building blocks, which can then be used to synthesize pharmaceuticals like dimestrol. Traditionally, converting methane into valuable chemicals has required high temperatures and pressures, or the use of more expensive and toxic rare metal catalysts.

The use of an iron-based catalyst offers several compelling advantages. Iron is an abundant, inexpensive, and far less toxic metal compared to the precious metals often employed in catalytic chemistry. Furthermore, the reaction operates under relatively mild temperatures and pressures, powered by LED light, significantly reducing energy demands and environmental impact. This innovative approach not only promises to cut drug manufacturing costs and emissions but also marks a crucial step toward a more sustainable and circular chemical economy, turning a potent greenhouse gas into a valuable resource for healthcare.